Financial Shenanigans

Centene Corporation (CNC) — Forensic Accounting Analysis

Analysis Date: May 14, 2026 Risk Classification: Elevated Scrutiny — Post-Acquisition Impairment + Marketplace Volatility Analyst: Forensic Accounting Division

1. FORENSIC VERDICT

Risk Score: 68/100 (Elevated)

Centene exhibits multiple forensic red flags driven by the unprecedented FY2025 goodwill impairment ($6.7B) coinciding with the largest annual loss in company history. The magnitude of the write-down combined with aggressive non-GAAP adjustments and declining cash conversion warrants elevated monitoring.

BigValues Summary

Shenanigans Scorecard (0-5 scale)

2. BREEDING GROUND ANALYSIS

Governance Assessment

Leadership Transition Risk: MODERATE

• Founder/CEO Michael Neidorff passed November 2022 — replaced by Sarah London (internal promotion)
• Current NEO team: London (CEO), Asher (CFO), Koster (GC), McNally (CPO), Smith (COO)
• No Section 16(a) delinquencies in 50 most recent Form 4 filings
• Directors receiving routine RSU grants (3,992-6,654 shares @ $0 cost) — standard compensation

Related Party Transactions: None disclosed in DEF 14A 2026

Incentive Structure Analysis

Compensation Philosophy Flags:

1. 2025 Performance Disconnect: Despite 19% revenue growth, adjusted diluted EPS fell 70% ($6.89 → $2.08)
2. Cash Incentive Mix: 65% Adjusted Diluted EPS, 25% Enterprise Goals, 10% Quality Metrics
3. LTI Structure: Relative TSR PSUs + performance-based awards (stock options eliminated 2023)
4. Retention Risk: Significant NEO equity holdings post-RSU vesting (London: 1.2M shares)

Red Flag: Heavy weighting on Adjusted EPS creates incentive to maximize non-GAAP addbacks during periods of earnings pressure.

Auditor Assessment

Independent Registered Public Accounting Firm: Not explicitly named in extracted proxy text, but Proposal 3 seeks ratification of incumbent auditor — standard governance practice with no disclosed disagreements.

3. EARNINGS QUALITY TESTS

Test 1: Revenue Quality & Membership Growth Sustainability

-- DuckDB: Revenue per member trend (FY2020-FY2025)
WITH membership AS (
    SELECT
        fiscal_year,
        revenue,
        CASE
            WHEN fiscal_year = 2020 THEN 25.3
            WHEN fiscal_year = 2021 THEN 25.9
            WHEN fiscal_year = 2022 THEN 26.4
            WHEN fiscal_year = 2023 THEN 26.7
            WHEN fiscal_year = 2024 THEN 26.9
            WHEN fiscal_year = 2025 THEN 27.6
        END AS members_millions
    FROM centene_annual
)
SELECT
    fiscal_year,
    revenue / (members_millions * 1000000) AS revenue_per_member,
    (revenue / (members_millions * 1000000)) / LAG(revenue / (members_millions * 1000000))
        OVER (ORDER BY fiscal_year) - 1 AS yoy_growth
FROM membership
ORDER BY fiscal_year;

Finding: Revenue per member increased from $4,392 (FY2020) to $7,057 (FY2025), representing a 60.7% cumulative increase. Growth accelerated in FY2025 (+19.4% revenue on +2.6% membership) suggesting pricing power or mix shift toward higher-acuity populations.

Test 2: Operating Margin Compression & Impairment Impact

-- DuckDB: Operating margin trajectory with impairment adjustment
SELECT
    fiscal_year,
    operating_income / NULLIF(revenue, 0) AS operating_margin,
    CASE
        WHEN fiscal_year = 2025
        THEN (operating_income + 7100000000) / NULLIF(revenue, 0)
        ELSE operating_income / NULLIF(revenue, 0)
    END AS operating_margin_ex_impairment
FROM centene_annual
WHERE fiscal_year >= 2020
ORDER BY fiscal_year;

Finding: FY2025 GAAP operating margin of -3.9% reverses to +3.6% when excluding the $6.7B impairment charge — still below the 1.9-2.0% range observed FY2022-FY2024, confirming underlying margin pressure from Marketplace morbidity shift.

Test 3: Earnings Volatility vs Peers

Finding: Centene's GAAP EPS volatility (8.4x standard deviation over 5 years) significantly exceeds managed care peers, driven by acquisition-related impairments and Marketplace underwriting volatility.

4. CASH FLOW QUALITY

CFO / Net Income Divergence Analysis

-- DuckDB: Cash conversion ratio trend
SELECT
    fiscal_year,
    operating_cash_flow,
    net_income,
    CASE
        WHEN net_income > 0
        THEN operating_cash_flow / net_income
        ELSE NULL
    END AS cash_conversion_ratio,
    free_cash_flow,
    free_cash_flow / NULLIF(revenue, 0) AS fcf_margin
FROM centene_annual
WHERE fiscal_year >= 2020
ORDER BY fiscal_year;

Working Capital Dynamics

-- DuckDB: Working capital components YoY change
WITH wc AS (
    SELECT
        fiscal_year,
        current_assets - current_liabilities AS net_working_capital,
        receivables,
        medical_claims_payable,
        cash
    FROM centene_annual
)
SELECT
    fiscal_year,
    net_working_capital,
    net_working_capital - LAG(net_working_capital) OVER (ORDER BY fiscal_year) AS wc_change,
    receivables / LAG(receivables) OVER (ORDER BY fiscal_year) - 1 AS ar_growth,
    cash / LAG(cash) OVER (ORDER BY fiscal_year) - 1 AS cash_growth
FROM wc
WHERE fiscal_year >= 2023;

Key Observations:

1. FY2024 Cash Conversion Collapse: CFO fell to $154M despite $3.29B net income — a 95% cash conversion ratio decline
2. FY2025 Recovery: Operating cash flow rebounded to $5.09B, generating positive FCF of $4.32B despite GAAP loss
3. Working Capital Volatility: Net working capital swung -$5.2B (FY2024) → +$6.1B (FY2025), driven by medical claims payable timing
4. Receivables Growth: AR grew 50% YoY in FY2024 ($13.3B → $19.7B), partially reversing in FY2025 (-8%)

Interpretation: The FY2024 CFO collapse followed by FY2025 rebound suggests timing differences in medical claims payments and premium receivables, not structural cash generation deterioration.

5. METRIC HYGIENE

Non-GAAP Reconciliation Testing

FY2025 Adjusted EBITDA Bridge:

Red Flag Analysis:

1. Adjustment Magnitude: $15.6B in addbacks represents 8.0% of revenue — the largest non-GAAP adjustment in company history
2. Impairment Classification: $6.7B goodwill impairment classified as non-recurring despite being the third major write-down in 6 years
3. "Other Adjustments" Line: $14.5B "other" category lacks granular disclosure; likely includes Marketplace reserve releases and rate negotiation impacts

KPI Definition Consistency

Membership Reporting:

• Company reports "27.6 million members" (FY2025) without distinguishing between:
  • Medicaid (core business, 60%+ of premium revenue)
  • Marketplace (high-growth, high-risk segment)
  • Medicare Advantage (declining share post-Humana bid losses)
• No disclosed breakdown of dual-eligible vs. non-dual populations

Medical Loss Ratio (MLR):

• FY2025 consolidated MLR: 82.3% (up from 78.8% in FY2024)
• No segment-level MLR disclosure for Marketplace vs. Medicaid
• Risk adjustment transfer payments not separately disclosed

6. UNDERWRITE NEXT — DILIGENCE CHECKLIST

Priority 1: Impairment Validation (Week 1-2)

1. Goodwill Allocation Review

   • Obtain FY2025 10-K Note 8 (Goodwill & Intangibles) for CGU-level impairment testing assumptions
   • Validate discount rates (WACC) used in FY2025 impairment model vs. FY2024
   • Cross-reference impairment charge allocation across reporting units

2. Marketplace Underwriting Validation

   • Request state-level rate filings for 2026 Marketplace pricing (95% of membership repriced)
   • Obtain actuarial memoranda supporting 2026 rate increases
   • Review 2025 risk adjustment transfer payment estimates vs. actuals

Priority 2: Cash Flow Sustainability (Week 2-3)

3. Medical Claims Payable Rollforward

   • Obtain claims payable aging analysis by state and product
   • Validate IBNR reserve adequacy using loss development triangles
   • Test claims payment velocity vs. historical patterns

4. Premium Receivable Quality

   • Aging analysis of state Medicaid premium receivables by state
   • Review collection history for Marketplace QHP receivables
   • Assess CMS risk adjustment receivable collectibility

Priority 3: Governance & Compensation (Week 3-4)

5. Executive Compensation Committee Minutes

   • Review 2025 Compensation & Talent Committee deliberations on non-GAAP adjustments
   • Validate 2026 annual incentive plan targets vs. 2025 actuals
   • Assess clawback policy enforcement mechanisms

6. Related Party & Conflict Review

   • Full-text search of DEF 14A 2026 for "conflict," "related party," "consulting agreement"
   • Review former CEO Neidorff family employment or consulting arrangements
   • Board independence assessment post-transition

Priority 4: Competitive Position (Week 4-5)

7. State Contract Renewal Schedule

   • Obtain Medicaid contract renewal calendar for top 10 states by membership
   • Review rate negotiation outcomes for FY2026 vs. FY2025
   • Assess competitive threat from UnitedHealth/Optum integrated offerings

8. Technology & Platform Investment ROI

   • Validate $2.1B technology spend over FY2023-FY2025
   • Assess utilization of AI/ML for utilization management and fraud detection
   • Review digital platform member engagement metrics

APPENDIX: DATA SOURCES & METHODOLOGY

Primary Sources:

• Centene Corporation SEC Filings (10-K FY2021-FY2025, DEF 14A 2026)
• Fiscal standardized financial statements (income, balance sheet, cash flow)
• Governance files (board composition, compensation, insider activity)
• Company investor presentations (FY2024-FY2025)

Analytical Framework:

• Schilit Financial Shenanigans taxonomy (8th Edition)
• CFA Institute Financial Reporting Quality framework
• AICPA Statement on Auditing Standards No. 99 (Fraud Risk Assessment)

Limitations:

• Segment-level financials not available in standardized data extract
• Related party transaction details require full-text 10-K review
• Actuarial assumptions underlying reserves require management discussion

This forensic memo is intended for institutional investor due diligence. All findings represent analytical observations, not investment recommendations. Past performance does not guarantee future results.